Amneal Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Amneal develops, manufactures, markets, and distributes generics, specialty branded medicines, and pharmaceuticals through its Generics, Specialty, and AvKARE segments. Figures below are in U.S. dollars.
Financial performance
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Net revenue | $659.2 million | $557.5 million |
| Gross profit; gross margin | $238.1 million; 36.1% | $178.2 million; 32.0% |
| Operating income (loss) | $(10.7) million | $34.4 million |
| Net income (loss), consolidated | $(81.7) million | $(10.1) million |
| Net loss attributable to Amneal; diluted loss per share | $(91.6) million; $(0.30) | $(6.9) million; $(0.05) |
| Operating cash flow | $(4.4) million | $139.7 million |
| Cash, cash equivalents, and restricted cash at quarter-end | $51.6 million | $151.1 million |
- Revenue by segment: Generics $391.3 million, up 13.8%; Specialty $105.2 million, up 14.8%; and AvKARE $162.7 million, up 33.3%.
- Profitability: Gross profit rose 33.6%, faster than revenue, with gross margin increasing 4.1 percentage points. The operating loss primarily reflects a $94.4 million opioid-litigation charge. Excluding that charge, operating results would have been materially different; the filing does not present this as an adjusted measure.
- Interest and taxes: Net interest expense was $65.7 million, up from $49.3 million, primarily due to higher rates on variable-rate debt. Income tax provision was $6.2 million; the effective tax rate was negative 8.2%.
- Cash flow: Investing activities used $19.8 million, including a $9.5 million sales-based milestone payment for a bevacizumab biosimilar. Financing activities used $23.2 million. Operating cash flow fell sharply year over year, in part because Q1 2023 benefited from timing of receivable collections and a $21.4 million Orion license payment.
- Debt and liquidity: At March 31, term loans totaled $2.529 billion gross and $2.411 billion net of issuance costs and current maturities; $179 million was outstanding on the revolving facility. The balance sheet also reports a $41.9 million related-party note payable. The company reported $46.5 million of cash and cash equivalents and access to $397.7 million of capacity under its main revolver and $28.0 million under the Rondo revolver.
Material changes and business developments
- Revenue growth reflected new generic launches and volume, including $24.6 million of year-over-year growth from biosimilars and $19.2 million from other new generic products, plus AvKARE distribution and government-label growth. Generics growth was partly offset by price erosion. Q1 2023 included a non-recurring $21.0 million Generics customer order.
- Specialty growth included $4.0 million of ONGENTYS sales following its Q1 2024 launch. The company resubmitted its IPX203 application to the FDA on February 7, 2024, after completing the requested QT study; the FDA decision date is August 7, 2024.
- Late in April 2024, after quarter-end, Amneal reached a settlement in principle for nationwide opioid cases. Proposed terms provide for $92.5 million in cash and $180 million in naloxone nasal spray over ten years; settling parties may elect cash for part of the product value, potentially increasing total cash payments to $137.5 million. The agreement remains subject to definitive documentation. At March 31, the company accrued a total opioid-litigation liability of $115.6 million, including $85.5 million classified as long-term.
- On April 30, 2024, Amneal completed the sale of an inactive Indian subsidiary for approximately $12 million in total consideration, comprising about $5 million cash and assumption of an approximately $7 million loan payable to another Amneal subsidiary.
Outlook, risks, and other notable matters
- Management believes available liquidity is sufficient for planned operations and obligations over the 12 months following the filing. The company expects 2024 capital expenditures of approximately $60 million to $70 million and estimates inflation-related cost increases of $15 million to $20 million for 2024, excluding rising interest rates. The filing does not provide clear full-year revenue or earnings guidance.
- Key risks include substantial indebtedness and interest-rate exposure, generic pricing competition and erosion, dependence on a limited number of customers and products, supply-chain disruptions, regulatory and product-approval uncertainty, and ongoing legal proceedings. Four customers each accounted for at least 10% of Q1 revenue; collectively they represented 69%. Three customers represented 84% of trade receivables at quarter-end.
- The company maintained a $566.0 million valuation allowance against deferred tax assets, citing cumulative consolidated pre-tax losses over the preceding three years. It stated that approximately $185 million of potential TRA liability was not recognized because realization of the related tax attributes was not considered more likely than not; $5.7 million of TRA liability was accrued as probable.
- Management concluded disclosure controls and procedures were effective as of March 31, 2024. The filing reported no material changes in internal control over financial reporting during the quarter and no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether the opioid settlement reaches a definitive agreement, its final cash-versus-product terms, payment schedule, and any effect on liquidity.
- Whether the FDA approves IPX203 by the August 7, 2024 decision date and the resulting launch timing and commercial costs.
- Whether operating cash flow improves as receivables and working-capital movements normalize, given the quarter’s cash use and lower cash balance.
- How variable interest rates, scheduled debt payments, and revolver availability affect interest expense and debt-service capacity.
- Whether new-product and segment growth can offset generic price erosion, customer concentration, and inflation-related cost increases.